Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.
News
In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, JNJ-90014496 (also referred to as JNJ-4496). The treatment has been demonstrated to have a strong success rate for treating patients who have relapsed or are […]
Johnson & Johnson reported encouraging new results from a Phase 1b trial that found its experimental oral medicine, bleximenib, given with the routine treatment regimen of venetoclax plus azacitidine, exhibited strong antileukemic activity in adults with acute myeloid leukemia (AML). The findings, reported at the 2025 European Hematology Association (EHA) […]
In an important milestone for the treatment of hepatitis C, AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion of MAVYRET® (glecaprevir/pibrentasvir), its pangenotypic, oral, direct-acting antiviral (DAA) therapy. The new indication now covers adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. This milestone approval distinguishes […]
Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
Gilead has paused dosing in its Phase 1b studies of GS-1720 and GS-4182—two promising long-acting HIV-1 therapies after identifying tolerability issues. No serious adverse events were reported, and the company is evaluating future development pathways.
Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March. Advancements in Immune Thrombocytopenia (ITP) Sanofi shared Phase 3 LUNA 3 study results on rilzabrutinib’s capability to treat the underlying immune dysregulation in ITP. An oral presentation reported rates of platelet response according to International Working Group (IWG) criteria—a major clinical endpoint for making treatment decisions. Two poster presentations reported the first efficacy and safety results from […]
AstraZeneca’s Calquence-based fixed-duration regimens gain EU approval for treating first-line CLL, offering patients a powerful, time-limited alternative to traditional continuous therapy.
Sanofi unveiled promising new data at ISTH 2025, spotlighting rilzabrutinib’s potential in immune thrombocytopenia and reinforcing its leadership in hemophilia care through advancements with ALTUVIIIO and QDENGA.
Roche’s Evrysdi® 5mg tablet for spinal muscular atrophy receives European Commission approval, offering a convenient, room-temperature stable treatment option for patients aged 2 and above.
